关键数据
1.610今开
1.640最高
36.00K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.35%换手率
1.560昨收
1.450最低
26.94K成交额
亏损市盈率静
-0.87市净率
0.00%股息率 TTM
-84.91%ROA
5.96052周最高
2.63量比
-22.58M净利润
10.43M总股本
-2.9077每股收益TTM
0.66Beta
-1205.58%ROE
2.22052周最低
12.18%振幅
33.53%毛利率
16.17M总市值
-6.41回报/风险
4.07%风险率
操作建议
Pluri Inc当前公司基本面数据相对谨慎,增长潜力较大。当前估值合理,在生物技术与医疗研究行业排名203/385位。机构持股占比非常高,近一月多位分析师给出公司评级为。最高目标价12.00。中期看,股价处于下降通道。近一个月,市场表现非常差,基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Pluri Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Ionis Pharmaceuticals Inc
IONS
25
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Pluri Inc简介
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
公司代码PLUR
公司Pluri Inc
CEOYanay (Yaky)
网址https://pluri-biotech.com/
公司股东
常见问题
Pluri Inc(PLUR)的当前股价是多少?
Pluri Inc(PLUR)的当前股价是 1.56。
Pluri Inc(PLUR)股票的每股收益(EPS TTM)是多少
Pluri Inc(PLUR)股票的每股收益(EPS TTM)是-3.56。